LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, has announced that management is planning to attend the World Health Expo 2027 in Dubai, United Arab Emirates, as part of a broader strategy to evaluate international healthcare expansion opportunities beyond its current Latin American focus. The announcement comes as the company continues to develop its digital healthcare ecosystem, which includes telehealth infrastructure, healthcare coordination technologies, pharmacy integration, insurance accessibility solutions, payment accessibility technologies, and artificial intelligence-driven platforms.
Management believes that participation in the World Health Expo 2027 will provide an important opportunity to engage with healthcare leaders, technology innovators, healthcare providers, government representatives, and potential strategic partners from around the world. The company intends to use the expo to assess international commercialization opportunities for its developing digital healthcare ecosystem and to evaluate potential strategic relationships, licensing opportunities, and regional collaborations. Additionally, the expo may offer insights into emerging trends in healthcare innovation, precision medicine, artificial intelligence, and digital health infrastructure.
The planned attendance builds upon LataMed AI’s recent international engagement initiatives, including attendance at HLTH Europe, and complements its continued expansion throughout Latin America. The company has recently announced strategic initiatives in Venezuela and is evaluating expansion opportunities in Colombia. Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “As we continue executing our long-term vision of building an integrated digital healthcare ecosystem, we believe it is important to evaluate opportunities beyond our existing markets. World Health Expo 2027 is expected to provide an outstanding opportunity to engage with healthcare leaders from around the world, better understand evolving global healthcare trends, and explore potential strategic relationships that may support the continued development and international expansion of the LataMed AI platform.”
Management emphasized that the attendance remains in the planning stage and forms part of a broader evaluation of future international growth opportunities. No assurance can be provided regarding the completion of any strategic relationships, licensing arrangements, commercial agreements, or international expansion initiatives that may arise from the planned attendance. The company also announced that it has received confirmation from FINRA that its previously announced 5-for-1 forward stock split and mandatory share exchange are expected to become effective at the opening of trading on Wednesday, July 15, 2026, subject to customary administrative processing. Shareholders holding shares through brokerage accounts or in electronic book-entry form are generally not expected to take any action, while shareholders holding physical stock certificates may exchange them through the company’s transfer agent.
LataMed AI is focused on building telehealth infrastructure, healthcare coordination tools, analytics capabilities, and AI-enabled healthcare solutions for emerging markets, with an initial regional focus on Latin America. For additional information, visit https://latamed.ai or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
